BMO Capital Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris has maintained an 'Outperform' rating on Biomarin Pharmaceutical (NASDAQ:BMRN), but lowered the price target from $102 to $100.
November 02, 2023 | 6:36 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BMO Capital has maintained an 'Outperform' rating on Biomarin Pharmaceutical but lowered the price target from $102 to $100.
The news is directly about Biomarin Pharmaceutical. The 'Outperform' rating suggests that BMO Capital expects the stock to do better than the market average, which is positive for the stock. However, the lowering of the price target might have a slight negative impact as it suggests a lower future value than previously expected.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100